# OnCo record nbtxr3 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/nbtxr3/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "nbtxr3" ;
  schema:name "NBTXR3 (hafnium oxide nanoparticles)"@en ;
  schema:alternateName "Hensify"@en, "JNJ-90301900"@en ;
  schema:description "NBTXR3 is Nanobiotix's radioenhancer: a single injection of hafnium oxide nanoparticles that makes ordinary radiotherapy hit harder inside the tumour. It carries a European CE mark for soft-tissue sarcoma and is in a phase 3 trial in head and neck cancer with Johnson and Johnson."@en ;
  schema:url <https://onco.cc/drugs/nbtxr3/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(19)30326-2>, <https://clinicaltrials.gov/search?intr=NBTXR3> ;
  onco:status "phase-3" ;
  onco:tag "radiation-wave3" ;
  onco:modality "Hafnium oxide nanoparticle radioenhancer, injected into the tumour" ;
  onco:approval "EU 2019: CE mark: locally advanced soft-tissue sarcoma of the limb or trunk wall, with preoperative radiotherapy" ;
  onco:cancers <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/head-and-neck/> ;
  onco:technologies <https://onco.cc/technologies/radiosensitisers/>, <https://onco.cc/technologies/imrt-igrt/> ;
  onco:companies <https://onco.cc/companies/nanobiotix/> ;
  onco:trials <https://onco.cc/trials/act-in-sarc/> .